



CARDI·OH

Ohio Cardiovascular and Diabetes Health Collaborative



In partnership with:



Cardi-OH ECHO

Health Equity and Cardiovascular Risk

December 7, 2023

Today's Presenters

FACILITATOR

Goutham Rao, MD, FAHA
Case Western Reserve University

DIDACTIC PRESENTER



LEAD DISCUSSANTS

Jim Werner, PhD, MSSA
Case Western Reserve University

Kathleen Dungan, MD, MPH
The Ohio State University

Marilee Clemons, PharmD
University of Toledo

CASE PRESENTERS

Alishea Gay, DNP, APRN-CNP
MetroHealth Bedford

Sue Paul, RPh
Crossroad Health Center

Disclosure Statements



- The following speakers and subject matter experts have a relevant financial interest or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation*:
 - Danette Conklin, PhD; Kathleen Dungan, MD, MPH; Adam T. Perzynski, PhD; Christopher A. Taylor, PhD, RDN, LD, FAND; Jackson Wright, MD, PhD
- The remaining speakers and subject matter experts have no financial relationships with any commercial interest related to the content of this activity:
 - Karen Bailey, MS, RDN, LD, CDCES; Kristen Berg, PhD; Elizabeth Beverly, PhD; Merilee Clemons, PharmD; Revital Gordodeski Baskin, MD; George Matar, MD; Kelsey Ufholz, PhD; Goutham Rao, MD; James Werner, PhD, MSSA
- The following members of the planning committee DO NOT have any disclosures/financial relationships from any ineligible companies:
 - Shari Bolen, MD; Anderson Christopher; Richard Cornachione; Carolyn Henceroth; Gillian Irwin; Michael Konstan, MD; Elizabeth Littman; Devin O'Neill; Steven Ostrolencki; Ann Nevar; Claire Rollins; Catherine Sullivan

* These financial relationships are outside the presented work.

** For more information about exemptions or details, see www.acme.org/standards

Questions



- For Kathleen's diabetes control presentation: should we briefly address perioperative management of the newer diabetes medicines? (GLP/SGLT as there has been much discussion on them in the last year?)

Questions

- For Danette's perimenopausal presentation: can/should we expand into more specifics of hormone replacement therapy? I got a little caught up in the slides on nonpharmacologic management → revisit the salient points of hormonal therapy with regard to cardiovascular risks?



Further Questions/Discussion?